· Dresden 2006 - Vom Nihilismus zum Algorithmus ·

Immunomodulatory Drugs in the Treatment of Myelodysplastic Syndromes

Literatur | Vortrag siehe hier

Autor: Prof. Dr. med. Eva Hellström-Lindberg, Karolinska Universitetssjukhuset, Stockholm

Quellenangabe: Deutsches MDS-Forum - Dresden 2006

Stand: 27.11.2006

A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes.
Br J Haematol 1998;103:1070-1074. PM:9886322
[Medline]
Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-Rauzy O, Quarre MC, Vassilief D, Varet B, Aouba A, Gardembas M, Giraudier S, Guerci A, Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P, Dreyfus F.
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies.
Br J Haematol 2005;131:609-618. PM:16351636
[Medline]
Greenberg P, Cox C, LeBeau MM.
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. PM:9058730
[Medline]
Hellstrom-Lindberg E, Ahlgren T, Beguin Y.
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
Blood 1998;92:68-75. PM:9639501
[Medline]
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Br J Haematol 2003;120:1037-1046. PM:12648074
[Medline]
Hellstrom-Lindberg E.
Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
Hematology Am Soc Hematol Educ Program 2005;161-167. PM:16304375
[Medline]
Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E.
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
Blood 2005;106:803-11. PM:15840690
[Medline]
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB.
Efficacy of lenalidomide in myelodysplastic syndromes.
N Engl J Med 2005;352:549-57. PM:15703420
[Medline]
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M.
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
J Clin Oncol 2005;23:7594-603. PM:16186598
[Medline]
Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ.
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
Blood 2002;100:1570-1574. PM:12176872
[Medline]
WHO.
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
IARC Press, Lyon 2001.